Table 2.
VTE risk assessment documentation and VTE prophylaxis prescribing guideline compliance pre- and post-intervention
| 2022 pre-intervention Group (n = 458) | 2023 post-intervention group (n = 392) | Difference (95% CI) | p-value | |
|---|---|---|---|---|
| Rate of VTE risk assessment documentation | ||||
| Overall | 105 (22.9%) | 207 (52.8%) | 29.9% (23.6–26.1%) | < 0.001 |
| Medical | 6 (3.3%) | 78 (42.2%) | 38.9% (31.3–46.4%) | < 0.001 |
| Surgical | 99 (35.9%) | 129 (62.3%) | 26.4% (17.8–35.1%) | < 0.001 |
| Rate of guideline-compliant VTE prophylaxis prescribing | ||||
| Overall | 255 (55.7%) | 273 (69.6%) | 13.9% (6.4–14.0%) | < 0.001 |
| Medical | 102 (56.0%) | 121 (65.4%) | 9.4% (− 0.05–19.3%) | 0.066 |
| Surgical | 153 (55.4%) | 152 (73.4%) | 18% (9.6–26.4%) | < 0.001 |
| Rate of guideline-compliant pharmacological VTE prophylaxis prescribing | ||||
| Overall | 350 (76.4%) | 330 (84.2%) | 7.8% (2.5–13.1%) | 0.005 |
| Medical | 116 (63.7%) | 137 (74.1%) | 10.4% (0.9–19.7%) | 0.033 |
| Surgical | 234 (84.7%) | 193 (93.2%) | 8.5% (3.0–13.9%) | 0.004 |
| Rate of guideline-compliant mechanical VTE prophylaxis prescribing | ||||
| Overall | 337 (73.5%) | 331 (84.4%) | 10.9% (5.5–16.3%) | < 0.001 |
| Medical | 168 (92.3%) | 168 (90.1%) | 2.2% (− 7.2–4.2%) | 0.606 |
| Surgical | 169 (61.2%) | 163 (78.7%) | 17.5% (9.5–25.5%) | < 0.001 |
CI, Confidence interval; VTE, Venous thromboembolism